{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:25:05Z","timestamp":1760711105575,"version":"3.37.3"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,10]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Immunogenicity and reactogenicity of COVID-19 vaccines have been established in various groups of immunosuppressed patients; however, studies involving patients with immune-mediated dermatological diseases (IMDDs) are scarce.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To investigate the influence of IMDDs on the development of SARS-CoV-2-specific immunity and side-effects following ChAdOx1-S[recombinant] vaccination.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This prospective cohort study included 127 patients with IMDDs and 97 participants without immune-mediated diseases who received ChAdOx1-S[recombinant]. SARS-CoV-2-specific immunity and side-effect profiles were assessed at 1 month postvaccination and compared between groups. Immunological (primary) outcomes were the percentages of participants who tested positive for neutralizing antibodies [seroconversion rate (SR)] and those who developed T-cell-mediated immunity demonstrated by an interferon-\u03b3-releasing assay (IGRA) [positive IGRA rate (+IGRA)]. Reactogenicity-related (secondary) outcomes were the unsolicited adverse reactions and worsening of IMDD activity reflected by the uptitration of immunosuppressants during and within 1 month of vaccination.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Overall, the SR for the IMDD group was similar to that of participants without immune-mediated conditions (75\u00b76 vs. 84\u00b75, P = 0\u00b7101), whereas + IGRA was lower (72\u00b74 vs. 88\u00b77, P = 0\u00b7003). Reactogenicity was similar between groups. No severe adverse reaction was reported. By stratifying the participants in the IMDD group according to individual disease, the immunogenicity of the vaccine was lowest in patients with autoimmune bullous diseases (AIBD) (SR 64\u00b75%, +IGRA 62\u00b79%) and highest in patients with psoriasis (SR 87\u00b77%, +IGRA 80\u00b77%). The reverse trend was found for vaccine-related reactions. Immunosuppressants were uptitrated in 15\u00b78% of cases; 75% of these were patients with AIBD.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Among participants with IMDDs, ChAdOx1-S[recombinant] showed good immunogenicity among patients with psoriasis, but demonstrated lower levels of immunogenicity for patients with AIBD. Some patients, especially patients with AIBD, should be closely monitored as they may require treatment escalation within 1 month postvaccination.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/bjd\/ljac045","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T22:50:07Z","timestamp":1673650207000},"page":"268-277","source":"Crossref","is-referenced-by-count":6,"title":["A real-world prospective cohort study of immunogenicity and reactogenicity of ChAdOx1-S[recombinant] among patients with immune-mediated dermatological diseases"],"prefix":"10.1093","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7931-3816","authenticated-orcid":false,"given":"Kumutnart","family":"Chanprapaph","sequence":"first","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8244-0098","authenticated-orcid":false,"given":"Chutima","family":"Seree-aphinan","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8336-1834","authenticated-orcid":false,"given":"Ploysyne","family":"Rattanakaemakorn","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cherrin","family":"Pomsoong","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanisa","family":"Ratanapokasatit","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chavachol","family":"Setthaudom","sequence":"additional","affiliation":[{"name":"Immunology Laboratory, Department of Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arunee","family":"Thitithanyanont","sequence":"additional","affiliation":[{"name":"Department of Microbiology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aphinyaphiwat","family":"Suriyo","sequence":"additional","affiliation":[{"name":"Immunology Laboratory, Department of Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanitta","family":"Suangtamai","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University , 270 Rama VI Road, Ratchathewi, Bangkok, 10400 , Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9723-0563","authenticated-orcid":false,"given":"P","family":"Suchonwanit","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, Faculty of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the COVIDVAC-DERM study group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"2023100520300506600_ljac045-B1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med"},{"key":"2023100520300506600_ljac045-B2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S1473-3099(21)00674-5","article-title":"Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study","volume":"22","author":"Desai","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2023100520300506600_ljac045-B3","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1080\/22221751.2021.1969291","article-title":"Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study","volume":"10","author":"Li","year":"2021","journal-title":"Emerg Microbes Infect"},{"key":"2023100520300506600_ljac045-B4","doi-asserted-by":"crossref","first-page":"102744","DOI":"10.1016\/j.jaut.2021.102744","article-title":"Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients\u2019 subgroups","volume":"125","author":"Ferri","year":"2021","journal-title":"J Autoimmun"},{"key":"2023100520300506600_ljac045-B5","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023100520300506600_ljac045-B6","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jaad.2021.07.054","article-title":"COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: review of available evidence","volume":"85","author":"Wack","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2023100520300506600_ljac045-B7","doi-asserted-by":"crossref","first-page":"e177-87","DOI":"10.1016\/S2665-9913(21)00394-5","article-title":"Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study","volume":"4","author":"Jyssum","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2023100520300506600_ljac045-B8","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/s41591-021-01469-5","article-title":"Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial","volume":"27","author":"Medeiros-Ribeiro","year":"2021","journal-title":"Nat Med"},{"key":"2023100520300506600_ljac045-B9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s13311-021-01165-9","article-title":"Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies","volume":"19","author":"Capone","year":"2022","journal-title":"Neurotherapeutics"},{"key":"2023100520300506600_ljac045-B10","doi-asserted-by":"crossref","first-page":"656362","DOI":"10.3389\/fimmu.2021.656362","article-title":"How to manage COVID-19 vaccination in immune-mediated inflammatory diseases: an expert opinion by IMIDs study group","volume":"12","author":"Ferretti","year":"2021","journal-title":"Front Immunol"},{"key":"2023100520300506600_ljac045-B11","doi-asserted-by":"crossref","first-page":"769845","DOI":"10.3389\/fmed.2021.769845","article-title":"Inactivated COVID-19 vaccine induces a low humoral immune response in a subset of dermatological patients receiving immunosuppressants","volume":"8","author":"Seree-Aphinan","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2023100520300506600_ljac045-B12","doi-asserted-by":"crossref","first-page":"e627","DOI":"10.1016\/S2665-9913(21)00212-5","article-title":"The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study","volume":"3","author":"Mahil","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2023100520300506600_ljac045-B13","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1136\/annrheumdis-2021-220597","article-title":"Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease","volume":"80","author":"Haberman","year":"2021","journal-title":"Ann Rheum Dis"},{"author":"European Medicines Agency","key":"2023100520300506600_ljac045-B14"},{"key":"2023100520300506600_ljac045-B15","first-page":"e60","article-title":"American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 3","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2023100520300506600_ljac045-B16","doi-asserted-by":"crossref","first-page":"e1010022","DOI":"10.1371\/journal.ppat.1010022","article-title":"Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination","volume":"17","author":"Davis","year":"2021","journal-title":"PLOS Pathogens"},{"key":"2023100520300506600_ljac045-B17","first-page":"168","article-title":"Establishment of adult peripheral blood lymphocyte subset reference range for an Asian population by single-platform flow cytometry: influence of age, sex, and race and comparison with other published studies","volume":"11","author":"Chng","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"key":"2023100520300506600_ljac045-B18","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1515\/CCLM.2001.179","article-title":"The existing interim consensus reference ranges and the future approach","volume":"39","author":"Dati","year":"2001","journal-title":"Clin Chem Lab Med"},{"key":"2023100520300506600_ljac045-B19","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/1536867X1301300304","article-title":"Computing adjusted risk ratios and risk differences in Stata","volume":"13","author":"Norton","year":"2013","journal-title":"Stata J"},{"key":"2023100520300506600_ljac045-B20","first-page":"408","article-title":"Sex and gender impact immune responses to vaccines among the elderly","volume":"30","author":"Fink","year":"2015","journal-title":"Physiology (Bethesda)"},{"key":"2023100520300506600_ljac045-B21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41541-019-0132-6","article-title":"The how\u2019s and what\u2019s of vaccine reactogenicity","volume":"4","author":"Herv\u00e9","year":"2019","journal-title":"NPJ Vaccines"},{"key":"2023100520300506600_ljac045-B22","doi-asserted-by":"crossref","first-page":"e42\u201352","DOI":"10.1016\/S2665-9913(21)00333-7","article-title":"Humoral and cellular \u00adimmunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study","volume":"4","author":"Mahil","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2023100520300506600_ljac045-B23","doi-asserted-by":"crossref","first-page":"e266\u20138","DOI":"10.1111\/jdv.17861","article-title":"Immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologic drugs","volume":"36","author":"Cristaudo","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100520300506600_ljac045-B24","doi-asserted-by":"crossref","first-page":"e52\u201361","DOI":"10.1016\/S2666-5247(21)00267-6","article-title":"Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis","volume":"3","author":"Cromer","year":"2022","journal-title":"Lancet Microbe"},{"key":"2023100520300506600_ljac045-B25","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"author":"World Health Organization","key":"2023100520300506600_ljac045-B26"},{"key":"2023100520300506600_ljac045-B27","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1136\/annrheumdis-2021-220862","article-title":"Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis","volume":"80","author":"Bugatti","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023100520300506600_ljac045-B28","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24894","article-title":"Reactogenicity of the messenger RNA SARS-CoV-2 vaccines associated with immunogenicity in patients with autoimmune and inflammatory disease","author":"Yang","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023100520300506600_ljac045-B29","doi-asserted-by":"crossref","first-page":"910.2","DOI":"10.1136\/annrheumdis-2021-eular.3822","article-title":"Pos1254\u2005incidence and outcome of Covid-19 in routine rheumatology care: data from a single outpatient center in Germany","volume":"80","author":"Werner","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"2023100520300506600_ljac045-B30","doi-asserted-by":"crossref","first-page":"258430","DOI":"10.1155\/2015\/258430","article-title":"Possible triggering effect of influenza vaccination on psoriasis","volume":"2015","author":"Gunes","year":"2015","journal-title":"J Immunol Res"},{"key":"2023100520300506600_ljac045-B31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1684\/ecn.2014.0358","article-title":"Proinflammatory cytokine responses in patients with psoriasis","volume":"25","author":"Kouris","year":"2014","journal-title":"Eur Cytokine Netw"},{"key":"2023100520300506600_ljac045-B32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11926-021-01046-2","article-title":"The use of COVID-19 vaccines in patients with SLE","volume":"23","author":"Tang","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"2023100520300506600_ljac045-B33","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1111\/ene.15028","article-title":"Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): early experience from a tertiary MS center in Israel","volume":"28","author":"Lotan","year":"2021","journal-title":"Eur J Neurol"},{"key":"2023100520300506600_ljac045-B34","article-title":"A self-resolving flare of psoriasis after COVID-19 vaccination","author":"Kaur","year":"2022","journal-title":"EMJ Rheumatol"},{"key":"2023100520300506600_ljac045-B35","first-page":"e22311","article-title":"Psoriasis flare-up after COVAXIN BBV152 whole virion inactivated vaccine","volume":"14","author":"Infimate","year":"2022","journal-title":"Cureus"},{"key":"2023100520300506600_ljac045-B36","doi-asserted-by":"crossref","first-page":"e15368","DOI":"10.1111\/dth.15368","article-title":"Psoriasis exacerbation after COVID-19 vaccination in high-risk group: how to manage it?","volume":"35","author":"Kabbani","year":"2022","journal-title":"Dermatol Ther"},{"key":"2023100520300506600_ljac045-B37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jdcr.2021.11.016","article-title":"New onset and exacerbation of psoriasis after COVID-19 vaccination","volume":"19","author":"Wei","year":"2022","journal-title":"JAAD Case Rep"},{"key":"2023100520300506600_ljac045-B38","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1038\/s41467-022-32321-0","article-title":"Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens","volume":"13","author":"Klemis","year":"2022","journal-title":"Nat Commun"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljac045\/48690290\/ljac045.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/2\/268\/51899138\/ljac045.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/2\/268\/51899138\/ljac045.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T20:53:08Z","timestamp":1696539188000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/188\/2\/268\/6765233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,10,21]]},"published-print":{"date-parts":[[2023,2,10]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljac045","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"type":"print","value":"0007-0963"},{"type":"electronic","value":"1365-2133"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,10,21]]}}}